Neurocrine Biosciences, Inc. (NBIX) Reports In-Line Q1 Loss of 1c
Tweet
Share
E-mailGet Alerts NBIX Hot Sheet
Price: $155.64 -1.71%
Revenue Growth %: +30.8%
Financial Fact:
Total operating expenses: 38.44M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Revenue Growth %: +30.8%
Financial Fact:
Total operating expenses: 38.44M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) reported Q1 EPS of ($0.01), in-line with the analyst estimate of ($0.01). Revenue for the quarter came in at $11.3 million versus the consensus estimate of $10.84 million.
For earnings history and earnings-related data on Neurocrine Biosciences, Inc. (NBIX) click here.
For earnings history and earnings-related data on Neurocrine Biosciences, Inc. (NBIX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- EU proposes to curb Airbnb and short-term rentals amid housing shortage
- Morgan Stanley Downgrades Sims Metal Management Ltd. (SGM:AU) (SMUPF) to Underweight
- RBC Capital Reiterates Outperform Rating on Aviva PLC (AV:LN) (AVVIY)
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
